Norway

Norway has a restrictive legal framework for classical psychedelics, with possession, use and trade generally prohibited outside explicit medical or scientific exceptions. In practice, access is concentrated in approved research settings, while ketamine-based care sits in a narrower medical pathway rather than a broad psychedelic access route.

Ask Blossom about this country

Data updated May 18, 2026

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inNorway.

1
Norway's near-term psychedelic market is not an access market; it is mainly a research and specialist-medicine market.
2
The strongest local activity appears to be around depression and PTSD-adjacent study topics, which matches Blossom's linked trial profile.
3
Oslo University Hospital and Østfold Hospital Trust are visible institutional anchors for Norwegian psychedelic-related clinical work.
4
The ketamine story is materially different from classical psychedelics: specialist use appears to be emerging, but esketamine reimbursement adoption remains unclear from the sources retrieved.
5
Because the most concrete recent public evidence is publication-level rather than policy text, access claims beyond general prohibition should be kept conservative on the country page.

Research and Access Snapshot

Blossom currently tracks 5 psychedelic clinical trials connected to Norway.

Active trials: 0
Total trials: 5
Stakeholders: 6
Events: 1

Top Compounds

MDMA(2)
Esketamine(1)
Ketamine(1)

Medical Access

Norway maintains a broadly prohibitive criminal/drug-scheduling regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, 5-MeO-DMT, 2C-series, ibogaine, ayahuasca), while ketamine-based treatments have an evolving medical pathway: esketamine (Spravato) has not been adopted into public reimbursement, whereas off-label intravenous racemic ketamine has been authorized for use within specialist services and publicly reimbursed for treatment-resistant depression under strict conditions as of August 25, 2025. Access to other psychedelics is...

View trials→View stakeholders→View events→Open access guide→

Regulatory Status

Norway's Medicines Act and narcotics rules restrict possession, use and supply of narcotic substances, and limit trade and dispensing to medical or scientific use unless a specific exception applies. That supports a broadly prohibitive position for psilocybin, MDMA, DMT, mescaline, 5-MeO-DMT, 2C-series, ibogaine and ayahuasca outside research or statutory exceptions. For ketamine, the legal and reimbursement picture is more nuanced: existing Norwegian sources confirm specialist-service reimbursement structures and a 2025 coding note referring to a decision that ketamine can be used for treatment-resistant depression, but I could not verify the full operational details of the pathway from primary sources here, so this part should be treated cautiously.